阿地唑仑甲磺酸盐 | 57938-82-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 中文名称: 阿地唑仑甲磺酸盐
• 英文名称: adinazolam methanesulfonate
• 英文别名: Adinazolam mesylate；1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine;methanesulfonic acid
• CAS: 57938-82-6
• 化学式: CH₄O₃S*C₁₉H₁₈ClN₅
• 分子量: 447.945
• InChiKey: FENBITQPWFCMEB-UHFFFAOYSA-N

物化性质

• 熔点：
  230-244°

计算性质

• 辛醇/水分配系数(LogP)：
  2.84
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 危险等级：
  6.1(b)
• 包装等级：
  III
• 危险类别：
  6.1(b)
• 危险品运输编号：
  UN 3249

反应信息

• 作为产物：
  描述：

  methane sulfonic acid 、 阿地唑仑 以 甲醇 、 乙酸丁酯 为溶剂， 生成 阿地唑仑甲磺酸盐
  参考文献：
  名称：

  Process to prepare .alpha.-chloroalprazolam

  摘要：

  使用磺酰卤化物直接卤代甲基苯二氮平（I），可制备.alpha.-卤代甲基苯二氮平（II）。

  公开号：

  US04663454A1

文献信息

• [EN] COMPOUNDS WHICH INCREASE APOLIPOPROTEIN A-1 PRODUCTION AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSES QUI AUGMENTENT LA PRODUCTION DE L'APOLIPOPROTEINE A-1 ET LEURS UTILISATIONS EN MEDECINE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2006032470A1

  公开（公告）日：2006-03-30

  The present invention relates to compounds of formula (I), pharmaceutically acceptable salts thereof, hydrates thereof, solvates thereof, prodrugs thereof and combinations thereof: wherein X represents CH or N; Y represents CH or N; R1 represents H or C1-2alkyl; R2 represents H or C1-4alkyl; R3 represents C1-6alkyl, carbocyclyl, carbocyclylC1-4alkyl, heterocyclyl or heterocyclylC1-4alkyl, wherein any of the carbocyclyl or heterocyclyl groups are optionally substituted by one or two groups selected from: halogen, C1-6alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, nitro, cyano, -COH, -COOH, C1-6alkoxycarbonyl, C1-6alkylcarbonyl, -C(OH)R5R6 (wherein R5 and R6 independently represent H or C1-6alkyl), -(CH2)nNR3aR3b and -O(CH2)pNR3aR3b (wherein n represents 1, 2 or 3, p represents 2 or 3 and R3a and R3b independently represent H, C1-6alkyl or carbocyclylC1-4alkyl, or R3a and R3b together with the interconnecting atoms form a 5 or 6-membered ring which ring optionally contains one or two heteroatoms independently selected from the group consisting of O, S and N); R4 represents H, hydroxy, halo, C 1-6 alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, C2-6alkenyl, C1-6alkoxy, haloC1-6alkoxy, carbocyclyl or heterocyclyl, wherein the carbocyclyl or heterocyclyl group is optionally substituted by one or two groups selected from: halogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, nitro and cyano; and provided that the compound is not: 7-chloro-5-phenyl-[1,2,4]triazolo[4,3-a]quinolin-4-amine; 7-chloro-1-methyl-5-phenyl[1,2,4]triazolo[4,3-a]quinolin-4-amine; or 7-chloro-5-(2-chlorophenyl)-1-methyl-1,2,4]triazolo[4,3-a]quinolin-4-amine. Also disclosed are pharmaceutical compositions containing the compounds and to their use in medicine. The compound exhibit increased apo-A1 production and are useful in the treatment for example a disease or condition caused by raised levels of LDL-cholesterol or by inflammation.

  本发明涉及以下式(I)的化合物，其在药学上可接受的盐、水合物、溶剂合物、前药及其组合物：其中X代表CH或N；Y代表CH或N；R1代表H或C1-2烷基；R2代表H或C1-4烷基；R3代表C1-6烷基、碳环烷基、碳环烷基C1-4烷基、杂环烷基或杂环烷基C1-4烷基，其中任何碳环烷基或杂环烷基基团可选择地由以下一种或两种基团取代：卤素、C1-6烷基、卤代C1-6烷基、羟基C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、硝基、氰基、-COH、-COOH、C1-6烷氧羰基、C1-6烷基羰基、-C(OH)R5R6（其中R5和R6独立地代表H或C1-6烷基）、-(CH2)nNR3aR3b和-O( )pNR3aR3b（其中n代表1、2或3，p代表2或3，R3a和R3b独立地代表H、C1-6烷基或碳环烷基C1-4烷基，或R3a和R3b与相互连接的原子一起形成一个含有O、S和N中独立选择的一个或两个杂原子的5或6元环，R4代表H、羟基、卤素、C1-6烷基、卤代C1-6烷基、羟基C1-6烷基、C2-6烯基、C1-6烷氧基、卤代C1-6烷氧基、碳环烷基或杂环烷基，其中碳环烷基或杂环烷基基团可选择地由以下一种或两种基团取代：卤素、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、硝基和氰基；并且前提是该化合物不是：7-氯-5-苯基-[1,2,4]三唑并[4,3-a]喹啉-4-胺；7-氯-1-甲基-5-苯基[1,2,4]三唑并[4,3-a]喹啉-4-胺；或7-氯-5-(2-氯苯基)-1-甲基-[1,2,4]三唑并[4,3-a]喹啉-4-胺。还公开了含有这些化合物的药物组合物以及它们在医学上的用途。该化合物具有增加apo-A1产生并且在治疗例如由于LDL胆固醇水平升高或由于炎症引起的疾病或病症中是有用的。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
  申请人：Johnson Bankole A.

  公开号：US20100076006A1

  公开（公告）日：2010-03-25

  The present invention provides for the use of combinations of drugs to treat addictive disorders.

  本发明提供了利用药物组合治疗成瘾性障碍的方法。
• Calcium channel blockers
  申请人：Massachusetts College of Pharmacy

  公开号：US20020115655A1

  公开（公告）日：2002-08-22

  The invention involves the identification of a family of compounds which block calcium channels. The compounds can be formulated in pharmaceutical carriers and administered to subjects. The compounds are useful for treating disorders associated with calcium channel activity, such as, cardiovascular diseases, for example hypertension, congestive heart failure, arrhythmia and angina.

  这项发明涉及识别一类阻断钙通道的化合物家族。这些化合物可以制成药物载体并用于治疗相关于钙通道活性的疾病，例如心血管疾病，如高血压、心力衰竭、心律失常和心绞痛。